What are the main indications for lapatinib? What diseases or conditions does it apply to?

Lapatinib is an oral small molecule tyrosine kinase inhibitor that mainly acts on the HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor) pathways. One of its main indications is for HER2-positive breast cancer, particularly in patients with advanced or metastatic breast cancer who have experienced resistance or progression to other treatments. Lapatinib is usually combined with capecitabine (capecitabine) to improve treatment response rate and prolong progression-free survival.

In addition to breast cancer, lapatinib has shown potential in some studies against other HER2-positive tumors, such as gastric and esophageal cancers, particularly in patients who have failed standard treatments. Although these indications have not yet been widely approved, combination therapy with lapatinib has been explored in some clinical practices to provide patients with more treatment options.

In addition, the use of lapatinib in some patients with brain metastases has also raised concerns. Due to its small molecular weight and certain ability to cross the blood-brain barrier, it may have certain advantages in the treatment of patients with brain metastases from HER2-positive breast cancer. However, this use is still in the clinical research stage, and its use must strictly follow the advice and supervision of professional doctors.

In general, the core indication of lapatinib is HER2 positive breast cancer, which provides a new treatment path especially when the disease progresses or other treatments are ineffective. With the deepening of research, its indications are expected to be further expanded, but currently the main application is still focused on the management of advanced HER2-positive breast cancer. Patients should undergo a clear HER2 test before use to ensure the effectiveness and safety of the treatment.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html